Role of hormone receptors and HER2 as prospective molecular markers for breast cancer: An update - ScienceDirect
Identification of gene markers for HER2+, Luminal A/B and TNBC. (A)... | Download Scientific Diagram
PLOS ONE: Serum HER2 Level Measured by Dot Blot: A Valid and Inexpensive Assay for Monitoring Breast Cancer Progression
Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence - Shi - 2019 - Cancer Medicine - Wiley Online Library
A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity - eBioMedicine
Cancers | Free Full-Text | HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness | HTML
Real-time detection of cancer marker, HER2, using a... | Download Scientific Diagram
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy | Scientific Reports
Novel treatment strategies for patients with HER2‑positive breast cancer who do not benefit from current targeted therapy drugs (Review)
Breast cancer: a new target? | Recherche animale
BMS-599626 (AC480), HER1 and HER2 inhibitor (ab142063) | アブカム
PLOS ONE: HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss
Therapeutic targeting of HER2–CB2R heteromers in HER2-positive breast cancer | PNAS
-Western-Blot-NBP2-34472-img0007.jpg "ErbB2/Her2 Antibody (CL0269) (NBP2-34472): Novus Biologicals")
ErbB2/Her2 Antibody (CL0269) (NBP2-34472): Novus Biologicals
Constitutively Activated STAT3 May Be a Predictive Marker for Resistance to Trastuzumab in Patients with HER2 Positive Breast Cancer | ESMO
Immunohistochemical profiles of ER, PR, HER2 and Ki-67 markers in the... | Download Scientific Diagram
Clinical applications of mouse models for breast cancer engaging HER2/neu
Addgene: pcDNA3-HER2-DMVF-181-N
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors - Cancer Treatment Reviews
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials - The Lancet Oncology
IVD Antibody & Immunoassay Development Services for HER2 Biomarker - Creative Biolabs
Multi-omics analyses identify HSD17B4 methylation-silencing as a predictive and response marker of HER2-positive breast cancer to HER2-directed therapy | Scientific Reports
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer - Annals of Oncology
Detection of cancer marker Her2 with QD-IgG.(A, C) Fixed breast cancer... | Download Scientific Diagram
